| Literature DB >> 17482818 |
Robert B Perni1, Gurudatt Chandorkar, Kevin M Cottrell, Cynthia A Gates, Chao Lin, Kai Lin, Yu-Ping Luong, John P Maxwell, Mark A Murcko, Janos Pitlik, Govinda Rao, Wayne C Schairer, John Van Drie, Yunyi Wei.
Abstract
Reversible tetrapeptide-based compounds have been shown to effectively inhibit the hepatitis C virus NS3.4A protease. Inhibition of viral replicon RNA production in Huh-7 cells has also been demonstrated. We show herein that the inclusion of hydrogen bond donors on the P4 capping group of tetrapeptide-based inhibitors result in increased binding potency to the NS3.4A protease. The capping groups also impart significant effects on the pharmacokinetic profile of these inhibitors.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17482818 DOI： 10.1016/j.bmcl.2007.03.090
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823